458 Prospective Randomized Study Confronting Monopolar Versus Bipolar Turp. 6 Months Follow Up Outcome

Bertolotto, Franco; Naselli, Angelo; Vigliercio, G.; Raggio, Maria Florencia; Puppó, P.

doi:10.1016/s1569-9056(07)60456-4

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characteristics of the included studies are detailed in the Appendix. Four studies were multi-institutional 4,20,24,48 and all other studies were single-institution. The included studies were performed between 2002 and 2016.…”

Section: Included Studiesmentioning

confidence: 99%

Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction: A Cochrane review

Alexander¹,

Scullion²,

Omar³

et al. 2020

CUAJ

View full text Add to dashboard Cite

Introduction: There remains uncertainty regarding the differences in patient outcomes between monopolar transurethral resection of the prostate (MTURP) and bipolar TURP (BTURP) in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO). Methods: A systematic literature search was carried out up to March 19, 2019. Methods in the Cochrane Handbook were followed. Certainty of evidence (CoE) was assessed using the GRADE approach. Results: A total of 59 randomized controlled trials (RCTs) with 8924 participants were included. BTURP probably results in little to no difference in International Prostate Symptom Score (IPSS) at 12 months (MD -0.24, 95% confidence internal [CI] -0.39–-0.09; participants=2531; RCTs=16; moderate CoE) or health-related quality of life (HRQOL) at 12 months (MD -0.12, 95% CI -0.25–0.02; participants=2004, RCTs=11; moderate CoE), compared to MTURP. BTURP probably reduces TUR syndrome (relative risk [RR] 0.17, 95% CI 0.09–0.30; participants=6,745, RCTs=44; moderate CoE) and blood transfusions (RR 0.42, 95% CI 0.30–0.59; participants=5727, RCTs=38; moderate CoE), compared to MTURP. BTURP may carry similar risk of urinary incontinence at 12 months (RR 0.20, 95% CI 0.01–4.06; participants=751; RCTs=4; low CoE), re-TURP (RR 1.02, 95% CI 0.44–2.40; participants=652, RCTs=6, I2=0%; low CoE) and erectile dysfunction (International Index of Erectile Function [IIEF-5]) at 12 months (MD 0.88, 95% CI -0.56–2.32; RCTs=3; moderate CoE), compared to MTURP. Conclusions: BTURP and MTURP probably improve urological symptoms to a similar degree. BTURP probably reduces TUR syndrome and blood transfusion slightly postoperatively. The moderate certainty of evidence available for primary outcomes suggests no need for further RCTs comparing BTURP and MTURP.

show abstract

Section: Included Studiesmentioning

confidence: 99%